Study #2021-1116
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, alternating with Azacitidine and Venetoclax, in Patients with Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes wi
MD Anderson Study Status
Enrolling
Treatment Agent
Cladribine, Cytarabine, Venetoclax, Azacitidine
Description
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Study phase:
Phase II
Physician name:
Guillermo Montalban Bravo
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.